clioquinol has been researched along with Idiopathic Parkinson Disease in 7 studies
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.
5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clioquinol treatment significantly prevented dopaminergic neurodegeneration and reduced α-synuclein-associated pathology in LB-injected mice, while no differences were observed with Zn supplementation." | 1.72 | The Zinc Ionophore Clioquinol Reduces Parkinson's Disease Patient-Derived Brain Extracts-Induced Neurodegeneration. ( Bezard, E; Bohic, S; Dehay, B; Doudnikoff, E; Teil, M; Thiolat, ML, 2022) |
| "Clioquinol (CQ) has been shown to have therapeutic benefits in rodent models of neurodegenerative disorders." | 1.56 | Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway. ( Cheng, A; Huang, C; Liu, W; Luo, Q; Shi, L; Shi, R; Xia, Y; Zeng, W; Zhengli, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Teil, M | 1 |
| Doudnikoff, E | 1 |
| Thiolat, ML | 1 |
| Bohic, S | 1 |
| Bezard, E | 1 |
| Dehay, B | 1 |
| Shi, L | 1 |
| Huang, C | 1 |
| Luo, Q | 1 |
| Xia, Y | 1 |
| Liu, W | 1 |
| Zeng, W | 1 |
| Cheng, A | 1 |
| Shi, R | 1 |
| Zhengli, C | 1 |
| Pretsch, D | 1 |
| Rollinger, JM | 1 |
| Schmid, A | 1 |
| Genov, M | 1 |
| Wöhrer, T | 1 |
| Krenn, L | 1 |
| Moloney, M | 1 |
| Kasture, A | 1 |
| Hummel, T | 1 |
| Pretsch, A | 1 |
| Sandor, C | 1 |
| Robertson, P | 1 |
| Lang, C | 1 |
| Heger, A | 1 |
| Booth, H | 1 |
| Vowles, J | 1 |
| Witty, L | 1 |
| Bowden, R | 1 |
| Hu, M | 1 |
| Cowley, SA | 1 |
| Wade-Martins, R | 1 |
| Webber, C | 1 |
| Kaur, D | 2 |
| Rajagopalan, S | 2 |
| Andersen, JK | 2 |
| Cole, GM | 1 |
| Yantiri, F | 1 |
| Kumar, J | 1 |
| Mo, JQ | 1 |
| Boonplueang, R | 1 |
| Viswanath, V | 1 |
| Jacobs, R | 1 |
| Yang, L | 1 |
| Beal, MF | 1 |
| DiMonte, D | 1 |
| Volitaskis, I | 1 |
| Ellerby, L | 1 |
| Cherny, RA | 1 |
| Bush, AI | 1 |
7 other studies available for clioquinol and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
The Zinc Ionophore Clioquinol Reduces Parkinson's Disease Patient-Derived Brain Extracts-Induced Neurodegeneration.
Topics: alpha-Synuclein; Animals; Brain; Clioquinol; Dopamine; Dopaminergic Neurons; Humans; Ionophores; Mic | 2022 |
Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Clioquinol; Disease Models, Animal; Haplorhin | 2020 |
Prolongation of metallothionein induction combats Aß and α-synuclein toxicity in aged transgenic Caenorhabditis elegans.
Topics: Aging; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modi | 2020 |
Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease.
Topics: Autopsy; Cells, Cultured; Clioquinol; Dopamine; Dopaminergic Neurons; Gene Expression Profiling; Gen | 2017 |
Chronic expression of H-ferritin in dopaminergic midbrain neurons results in an age-related expansion of the labile iron pool and subsequent neurodegeneration: implications for Parkinson's disease.
Topics: Aging; Animals; Apoferritins; Chelating Agents; Clioquinol; Dopamine; Gene Expression Regulation; Ir | 2009 |
Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Animals; Clioquinol; Ferritins; Gen | 2003 |
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2003 |